The Use of Priscoline in the Treatment of the Hypoperfusion Syndrome

Abstract

In line with the report on pulmonary hypoperfusion as a possible mechanism in the etiology of hyaline membrane disease, we have been carrying out studies on newly born infants with this disease in order to correct the diminished pulmonary blood flow. We have used drug therapy on a total of 5 infants, and this has been associated with considerable normalizing in various abnormalities caused by the disease. We have first corrected acidosis when present, and then given tolazoline HC1 (Priscoline).